Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02752035
Title	A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy
Recruitment	Completed
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Astellas Pharma Global Development, Inc.
Indications	acute myeloid leukemia
Therapies	Gilteritinib Azacitidine + Gilteritinib Azacitidine
Age Groups:	senior \| adult
Covered Countries	USA \| POL \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUS